Published in Mediterr J Hematol Infect Dis on May 01, 2015
Anemia in the Elderly: not Always what it Seems. Mediterr J Hematol Infect Dis (2016) 0.75
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Proposals for the classification of the myelodysplastic syndromes. Br J Haematol (1982) 10.90
The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 10.87
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica (2005) 4.34
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol (2011) 2.69
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
The bone marrow aspirate of healthy subjects. Br J Haematol (1996) 2.41
Should clinical hematologists put their microscopes on eBay? Haematologica (2014) 1.99
The genetic basis of myelodysplasia and its clinical relevance. Blood (2013) 1.95
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia (2008) 1.89
Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res (2011) 1.82
Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol (1995) 1.80
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol (2008) 1.68
Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood (2002) 1.49
The significance of bone marrow cell morphology and its correlation with cytogenetic features in the diagnosis of MDS-RA patients. Leuk Res (2009) 1.46
Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res (2013) 1.42
Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol (2011) 1.42
Myelodysplastic/myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program (2011) 1.38
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood (2014) 1.29
Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North Am (2010) 1.29
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica (2012) 1.28
Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol (2010) 1.26
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia (2007) 1.21
Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia (1998) 1.18
Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica (2009) 1.17
Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res (2007) 1.16
Morphological evaluation of monocytes and their precursors. Haematologica (2009) 1.13
Myelodysplastic syndromes. Am J Clin Pathol (2009) 1.12
Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification. Mod Pathol (2008) 1.12
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood (2011) 1.10
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia (2005) 1.09
Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica (2011) 1.07
Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk Res (1999) 1.06
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia (2014) 1.02
Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res (2012) 0.98
Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary? Haematologica (2013) 0.97
Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest (2009) 0.97
Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol (2005) 0.88
Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. Am J Cancer Res (2010) 0.87
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res (2007) 0.86
Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget (2010) 0.85
Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows. Leuk Res (2009) 0.83
Border between aplastic anemia and myelodysplastic syndrome. Int J Hematol (2013) 0.81
Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. Leuk Res (2011) 0.80
I walk the line: how to tell MDS from other bone marrow failure conditions. Curr Hematol Malig Rep (2014) 0.79
The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. Cancer (2009) 0.79
Myelodysplastic syndromes. Semin Diagn Pathol (2011) 0.79
Myelodysplastic syndrome associated with bone marrow fibrosis. Leuk Lymphoma (1992) 0.79
Classification and morphologic features of the myelodysplastic syndromes. Semin Oncol (1992) 0.79
Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia. Eur J Haematol (2009) 0.79
Morphology, cytogenetics and classification of MDS. Best Pract Res Clin Haematol (2013) 0.78
Diagnostic significance of dysplastic features of peripheral blood polymorphs in myelodysplastic syndromes. Leuk Res (1989) 0.76
Diagnosis of myelodysplastic syndromes in cytopenic patients. Hematol Oncol Clin North Am (2011) 0.76
Current pathology practices in and barriers to MDS diagnosis. Leuk Res (2013) 0.76
A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes. Leuk Lymphoma (2000) 0.76